DRL acquires injectable portfolio from US-based Eton Pharma for $50 million

The portfolio includes the Biorphen (phenylephrine hydrocholoride) injection and Rezipres (ephedrine hydrochloride) injection NDAs (new drug application) with nine separate combinations of strengths and presentations and one first- to-file approved ANDA for Cysteine Hydrochloride for the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/azGYp6u
via IFTTT